Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 2/20 | 0.57 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.53 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.50 |
| ▸ | KCNH3 | Q9ULD8 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | KDR | P35968 | 2/20 | 0.49 |
| ▸ | PLK4 | O00444 | 1/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.49 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31381352 | 0.86 | MAP3K5 (0.60) | AURKAROCK1MAP3K5NPC1RAB9A | |
| Benzene SCHEMBL28188863 | 0.86 | MAP3K5 (0.60) | AURKAROCK1MAP3K5NPC1RAB9A | |
| SCHEMBL167891 | 0.86 | MAP3K5 (0.60) | AURKAROCK1MAP3K5NPC1RAB9A | |
| SCHEMBL27770482 | 0.86 | MAP3K5 (0.60) | AURKAROCK1MAP3K5NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL8807679 | 0.84 | MAP3K5 (0.58) | AURKAROCK1MAP3K5NPC1RAB9A | |
| SCHEMBL4573935 | 0.84 | MAP3K5 (0.58) | AURKAROCK1MAP3K5NPC1RAB9A | |
| SCHEMBL3339632 | 0.83 | NPY5R (0.55) | AURKAROCK1MAP3K5NPC1RAB9A | |
| SCHEMBL27610222 | 0.83 | ROCK1 (0.53) | AURKAROCK1MAP3K5RAB9AMEN1 | |
| SCHEMBL6037487 | 0.83 | ROCK1 (0.53) | AURKAROCK1MAP3K5KDRPLK4 | |
| SCHEMBL4030061 | 0.83 | MAP3K5 (0.55) | AURKAROCK1MAP3K5MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105753793-B | Fragrant formyl urea coupling quinazoline compounds and preparation method thereof, pharmaceutical composition and medicinal usage | 河北医科大学 | 2018-09-04 | — | — | CN | disclosed |
| CN-103382182-B | Phenylurea coupling quinazoline compounds and preparation method thereof, pharmaceutical composition and medicinal usage | 河北医科大学 | 2016-08-10 | — | — | CN | disclosed |
| US-8673929-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20100143299-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100143299-A1 | 4,6-DI- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS | OPRD1, IFNAR1, NR4A1 | AURKA 3298/4885ROCK1 3105/4885MAP3K5 3016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.